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Background: Polypharmacology plays an important part in drug discovery, and remains a major challenge in
drug development. Identification of the underlying polypharmacology of a drug, as well as development of
polypharmacological drugs, have become important issues in the pharmaceutical industry and academia.
Description: Herein, through data mining of the Protein Data Bank (PDB), a free, Internet-accessible database called the
Multiple Target Ligand Database (MTLD; www.mtdcadd.com) was constructed. The MTLD contains 1,732 multiple-target
ligands (MTLs) which bind to 14,996 binding sites extracted from 12,759 PDB structures. Among MTLs, 222 entries are
approved drugs and 1,334 entries are drug-like compounds. The MTLD could be an extremely useful tool in the
development of polypharmacological drugs. It also sheds light on the side effects of drugs through anticipation of
their multiple functions and similarities in the binding sites of multiple targets. The entire database is free for online
searching, browsing, and downloading.
Conclusion: As a crucial expansion of the PDB, increasing numbers of MTLs will be included in the MTLD. Eventually,
it will become an efficient platform to obtain useful information on MTLs and their underlying polypharmacology.
Keywords: Polypharmacology, Multiple-target ligands, Database, Drug discoveryBackground
“Polypharmacology” (also termed “drug promiscuity”) re-
fers to the action of a single drug on multiple targets
through a single pathway or multiple pathways. This
phenomenon has been regarded to be the main cause
for the severe adverse effects or toxicities of several
drugs approved since the 1990s [1-3]. Based on the ex-
ponential growth of molecular data and rapid advances
in drug development, evidence suggests that polyphar-
macology is also important for drug efficacy. For in-
stance, clozapine is the “gold standard” anti-psychotic
drug exhibiting beneficial effects via complicated inter-
actions with multiple target networks [4]. Several highly
efficacious drugs such as salicylate, metformin, or ima-
tinib exhibit enhanced therapeutic efficacy through in-
teractions with multiple targets simultaneously.
In general, it is accepted that the activity towards a
single target is not sufficient for a complex disease in-
volving multiple pathogenic factors (e.g., cancer, diabetes* Correspondence: zhoujinming@imb.pumc.edu.cn
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unless otherwise stated.mellitus, neurodegenerative syndrome, cardiovascular
diseases). Importantly, some of the undesired side effects
are due to drugs not hitting their targets, which can con-
fer potential repurposing opportunities for these drugs
and provide novel strategies in drug design.
Taken together, polypharmacology plays an important
part in drug discovery and remains one of the major chal-
lenges in drug development. It opens avenues for rational
design of new agents that are more efficient and less toxic
than their predecessors [5-10]. Drug discovery using a
polypharmacology approach has become a hot topic in
the pharmaceutical industry and in academia [5-7,11].
There are hundreds of publicly available databases on
drug discovery Protein Data Bank (PDB) [12], DrugBank
[13], Kyoto Encyclopedia of Genes and Genomes (KEGG)
[14], ZINC [15], Chemical database of European Molecular
Biology Laboratory [16], and Therapeutic Target Database
[17]. Such databases are key resources that integrate di-
verse information such as molecular pathways, crystal
structures, binding experiments, side effects, and drug tar-
gets. Such information is also very useful in prospective
drug design using a polypharmacology approach. How-
ever, finding information on polypharmacological agentsan Open Access article distributed under the terms of the Creative Commons
org/licenses/by/4.0), which permits unrestricted use, distribution, and
riginal work is properly credited. The Creative Commons Public Domain
rg/publicdomain/zero/1.0/) applies to the data made available in this article,
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tained in such databases. Thus, development of a novel
data-mining method archiving polypharmacological infor-
mation is needed.
The PDB is a repository of detailed three-dimensional
(3D) structural information of proteins and other mole-
cules, including information on the binding between
ligands and proteins. It is extremely helpful in the elucida-
tion of ligand promiscuity. Recently, based on the infor-
mation obtained from the PDB, evidence indicates that
similarities in binding sites among multiple proteins and
the molecular complexity of a ligand could be reasons for
the polypharmacology of drugs [18,19]. As a result, several
datasets of multiple-target ligands (MTLs) derived from
the PDB have been built by comparing the similarities
of binding sites (e.g., Kahraman, Extended Kahraman,
Huang) [20,21]. However, the overall entries of MTLs in
these datasets are ≤100. Through analyses of ligand pro-
miscuity based on the PDB, an additional two datasets
have been generated, containing 164 and 247 entries, re-
spectively [18,19]. However, these datasets do not include
all of the potential MTLs in the PDB, and the information
in these datasets is not sufficient. Hence, a database con-
taining all of the potential MTLs in the PDB is needed.
Herein, a database termed the Multiple Target Ligand
Database (MTLD, www.mtdcadd.com) based on 3D struc-
tural data extracted from the PDB has been constructed.
The MTLD contains all of the ligands binding to MTLs
and sheds light on the side effects through anticipation of
their multiple functions as well as the similarities in the
binding site of multiple targets. The entire database is free
for online searching, browsing, and downloading. Collec-
tively, the MTLD is extremely useful for the development
of polypharmacological drugs, and provides various poten-
tial candidates for further optimization.Figure 1 Dataset collection of the MTLD.Construction and content
Original structural datasets were downloaded from the
File Transfer Protocol (FTP) archive (version: December
2012) of the PDB using the script “rsyncPDB.sh”. Datasets
were data-mined step-by-step automatically through the
command programs written in Perl language (Figure 1).
Atomic structures with a resolution of ≥3.0 Å could be
inferred. Hence, X-ray protein structures with a reso-
lution <3.0 Å (67,793 entries) from the PDB were se-
lected for the extraction of ligands and their binding
sites. To avoid selection of solvent molecules, ligands
containing >8 heavy atoms were extracted from selected
PDB files. As a result, 62,423 ligand coordinate files were
obtained. Binding sites were defined as all of the protein
residues within a radius of 6.0 Å of each atom in binding
ligands. Binding sites with >5 residues were outputted,
and 54,936 binding sites were extracted, which could
bind with 12,138 ligands. Among these ligands, 3,371
ligands were found to bind to more than one PDB struc-
ture, and these ligands were chosen for the next filtra-
tion. To remove the redundancy of crystal structural
entries bound to the same ligand, the sequence identity
between protein pairs was restricted to <35%. Eventually,
1,732 MTLs were extracted from the PDB and archived
in the MTLD.
Each ligand entry contains five pieces of information.
First, the 3D structures of the ligand extracted directly
from the known crystal structures are provided. Second,
the two-dimensional structure of the ligand that had
been converted into “SMILES” format is given. Third,
the structures of the binding site that were outputted
according to the coordinates of the ligand are detailed.
Fourth, the original crystal structures from the PDB to
which the ligand binds is given. Last, information on
the sequence of the involved proteins downloaded from
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www.uniprot.org) is provided.
Altogether, the MTLD comprises 1,732 MTLs, ≈14.3%
of total unduplicated extracted ligands (12,138 entries),
which bind with 14,996 binding sites from 12,759 crystal
structures. Overall, the MTLD (Table 1) is the most
comprehensive, detailed and complete database of MTLs
compared with other existing databases on MTLs.
Statistical analyses for the MTLD
To better understand constitution of the MTLs in the
MTLD, statistical analyses of the MTLD were undertaken
(Figure 2). First, the KEGG database (a database of small
molecules, biopolymers, and other chemical substances
relevant to biological systems) was used to analyse the
relationship between MTLD entries and biological pro-
cesses. In total, 815 MTL entries in the MTLD also
belonged to the KEGG database (≈47.1% of overall entries;
Figure 2A), which includes various amino acids, saccha-
rides, nucleotides, and lipids. Similarly, in contrast to the
known drugs listed in the DrugBank, 222 approved drugs
were found in the MTLD (≈12.8% of overall entries;
Figure 2B). In particular, by using the module “QuaSAR-
Descriptor” included in Molecular Operating Environment
(Chemical Computing Group, Montreal, Canada) accor-
ding to Lipinski's rule of five, 1,334 entries were predicted
to be drug-like compounds (≈76.9% of overall entries;
Figure 2C). Analyses of the distribution of the molecular
weights of MTLs in the MTLD indicated that most of the
MTLs had molecular weights <500 Da, and that a very
small portion of MTLs had a molecular weight >1000 Da
(Figure 2D). Thus, statistical analyses suggested that the
MTLD could be highly relevant to biological processes
and the action mechanism of drugs.
Among 1,732 MTLs, ≈45.9% ligands (795 entries) were
bound to two distinct proteins (Figure 2E), which was
lower than the result (65%) reported by Noé Sturm et al.
[19]. This result was probably caused by using a different
source of datasets when they adopted the sc-PDB
(a database derived from the PDB). Notably, 222 ligands
were bound to >10 proteins, including approved drugsTable 1 Comparison of the MTLD with other datasets of
multiple-target ligands
Dataset MTL entries PDB structures Accessibility
Huang 12 143 Yes
Kahraman 9 100 Yes
Extended Kahraman 10 972 Yes
Homogeneous 10 100 Yes
PDB MTL I 164 712 No
PDB MTL II 518 8166 No
MTLD 1732 12759 Yessuch as isotretinoin, spermidine, and salicylic acid. The
promiscuity of a ligand is related to its conformational flexi-
bility [19]. Hence, analyses of the conformational com-
plexity of the extracted PDB structures for each ligand were
conducted through structural alignment using Multiscale
Modeling Tools for Structural Biology (Scripps Research
Institute, San Diego, CA, USA). The root-mean-square
deviation (RMSD) of structure pairs was calculated after
the alignment. The maximal RMSD value of the struc-
ture pairs was taken to be a criterion of conformational
change. Computed RMSD values of most MTLs (1,270
entries, ≈73.3%) were <2.0 Å (Figure 2F), indicating that
most of the MTLs could bind to different proteins by
adopting a similar conformation. However, further com-
prehensive analyses are needed to identify the effects of
other parameters such as the: molecular size and flexibility
of MTLs; number of potential targets; mode of interaction
between MTLs and targets.
Internet interface of the MTLD
The Internet server of the MTLD (mtdcadd.com) is a
free, accessible database of MTLs obtained from data
mining of the PDB. The Internet server was built using
MySQL, Java, Javascript, and HTML languages on a ma-
chine with four 2.13-GHz processors. Java and Javascript
enable the search function. Java Runtime Environment
needs to be installed on the client/customer side. The
3D structures of ligands and proteins were visualized
using an open-source Java viewer: Jmol. The structural
similarity of ligands was calculated using the FP2 finger-
print through an open-source chemical toolkit: Open
Babel.
The MTLD is an easily usable and fully searchable
database with many built-in tools. On the MTLD home-
page and “About” webpage, a brief introduction of the
MTLD is given. The “Download” webpage provides the
download option for all data, including approved drugs,
KEGG ligands, and some kinase inhibitors. All can be
downloaded conveniently. On the “Statistics” webpage,
the results of statistical analyses are provided (as men-
tioned above) and more statistical results will be re-
vealed on this page in the future.
The link “Search” provides three options. The first is the
“Protein” option, which can be searched according to the
name, PDB-ID, or UniProt-ID of proteins. For example, a
query using the protein name “androgen receptor” was
submitted. Five entries were presented in tabular format
on the results page showing the: 3D structures of ligands;
name, formula, molecular weight of the ligand; ligand-ID
of the PDB. One can also proceed to each corresponding
webpage of each entry with hyperlinks to other data-
bases such as the PDB, KEGG, DrugBank, and UniProt
(Figure 3A). The “Lig” option can be searched by the
ligand-ID of the PDB, ligand name, or InChI key. For
Figure 2 Statistical analyses for entries in the MTLD. (A) 815 (47.1%) entries belong to the Kyoto Encyclopedia of Genes and Genomes database;
(B) 222 (12.8%) entries are approved drugs from the DrugBank database; (C) 1334 (76.9%) entries are drug-like compounds according to Lipinski’s
rule of five; (D) molecular weights of most ligands are ≤500 Da. (E) Statistical analyses of the target number of ligands included in the MTLD: 795
ligand entries bind two targets; 551 ligand entries bind 3–5 targets; 189 ligand entries bind 6–10 targets; and 197 ligand entries bind to >10
targets; (F) Comparison of the conformation of a ligand bound to different targets. Root-mean-square deviation (RMSD) value was calculated to
evaluate the change in conformation: the RMSD value of most ligands was ≤2 Å, indicating a small conformational change.
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ching, 16 non-redundant protein targets binding with it
were obtained on the results page (Figure 3B). The
“structural” option enables users to draw the queried
structures of ligands in the Journal Molecular Editor win-
dow. For example, users draw dihydrotestosterone as a
query compound with a Tanimoto score cutoff of 0.8
(the Tanimoto score cutoff can be selected from the drop-
down menu). Fifteen “hits” were presented in a tabular
format on the results page (Figure 3C).
Discussion
We have demonstrated that the MTLD provides readily
accessible information for MTLs (e.g., binding sites ex-
tracted from PDB structures, drug-like information,
structural similarity of ligands) as well as convenient
hyperlinks to databases such as UniProt, DrugBank,
KEGG, and the PDB. In addition, redundancy is very
common in the PDB. For example, in the PDB, dihydro-
testosterone has been found to bind with 37 proteins,
which belong to only three targets (Table 2). In such cir-
cumstances, the MTLD exhibits the target information
of MTLs clearly by filtration of redundant information.
However, filtration can result in the loss of some im-
portant information, especially for some kinase families,which have very similar amino-acid sequences. In such
cases, switching off the “35% Sequence Identity Filtration”
option in the search webpage gives the full list of proteins
to which a ligand binds.
A crystal structure with a bound ligand does not
necessarily mean firm binding. The binding affinity or
binding energy of the ligand are important parameters
to show if the interaction between the ligand and protein
is specific, which can help to judge the “true” target of
the ligand. Thus, a link to BindingDB was added on the
ligand webpage, and one can find the reported data on
binding affinity on the linking page. Moreover, most data
on the binding affinity of complexes were not available.
Hence, evaluation of the binding free energy using the
X-Score method according to the complex coordinate
[22] was undertaken, and the value of the binding free
energy of the complex shown on the webpage. Further-
more, the crystal structures of some target classes (e.g.,
kinases) can be obtained much more readily than those of
other target classes (e.g., G protein-coupled receptors). In
such cases, a bias may be added into the MTLD because
the target will not be shown in the database if a crystal
structure for that target has not been solved. Further
enhancement is needed to try to include such targets into
the MTLD.
Figure 3 Three examples of searches of MTLs on the MTLD Internet server: (A) ligands that bind to the androgen receptor were queried in the “Protein”
option; (B) ligands with the ligand-ID of “SAL” were queried in the “Lig” option; (C) ligands with structural similarity to that of dihydrotestosterone were
queried in the “Structural” option.
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Most of the entries in the MTLD are based on drugs.
Hence, the MTLD should be useful for developing poly-
pharmacological agents, and may provide potential can-
didates for further optimization. For example, estrogen
receptor-alpha is a drug target for treating breast cancer,
and 17-hydroxysteroid dehydrogenase (17HSD1) is aputative target for endocrine therapy of hormone-
dependent breast cancer [23]. By searching the MTLD, a
ligand, estrogen (ligand-ID: EST) binding to 17HSD1
(PDB-ID: 1FDS) and estrogen receptor (PDB-ID: 3Q95)
was found. Thus, polypharmacological drugs that act on
both targets could be designed based on the structure of
estrogen. Conversely, software called Binding Site Match
Table 2 Multiple targets of selected drugs and natural



















































Table 2 Multiple targets of selected drugs and natural
products in the MTLD (Continued)
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according to their similar physiochemical properties and
generate common sites. Binding Site Match Maker could
be another option for the design of polypharmacological
drugs.
The MTLD can shed light on the multiple mecha-
nisms of action of drugs or natural products. For ex-
ample, imatinib is an efficacious drug for the treatment
of chronic myeloid leukaemia (CML). Imatinib prevents
Bcr-Abl protein from exerting its actions in the onco-
genic pathway in CML [24]. By searching the MTLD,
apart from Bcr-Abl, imatinib was found to bind to
mitogen-activated protein kinase 14, ribosyldihydroni-
cotinamide dehydrogenase, tyrosine-protein kinase Syk,
and c-Kit kinase. The natural product resveratrol (which
is present in red wine) exhibits considerable chemical di-
versity and biological activities [25]. In the MTLD, res-
veratrol was found to bind with seven targets. More
examples of drugs and natural products are listed in
Table 2.
Information obtained from the MTLD can be used to
address the mechanism of action of the adverse side ef-
fects of drugs. For example, the methylxanthine derivative
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airflow obstruction) can cause headaches, agitation, and
other adverse neuronal side effects. Upon searching the
MTLD, pyridoxal kinase was found to be one of the tar-
gets of theophylline, which could be a possible underlying
mechanism of the neurotoxic effects of theophylline [26].
Likewise, pioglitazone (used for treating type-2 diabetes
mellitus) exhibits neuronal side effects, including central
nervous system (CNS) depression. Upon searching the
MTLD, it was found that pioglitazone can bind to mo-
noamine oxidase B, which may be responsible for CNS
depression [27].
Similarities in the binding site have important roles in
polypharmacology [18]. Several methodologies have been
developed to evaluate similarities in binding sites, such
as SiteComp [28] and MultiBind [29]. These methodolo-
gies provide useful tools to predict the binding-site simi-
larity of proteins but because of their incompleteness,
need to be improved [30]. In such circumstances, the
MTLD could provide various binding sites as the trai-
ning sets or testing sets for the development of novel
methodologies for comparisons of binding sites.
Conclusion
Here we describe development of a comprehensive,
Internet-accessible database called the MTLD based on
datasets extracted from the PDB. To date, the MTLD
comprises 1,732 MTLs that bind to 14,996 binding sites
extracted from 12,759 PDB structures. In the MTLD, the
222 entries are approved drugs and 1,334 entries are drug-
like compounds. Thus, the MTLD could be extremely
helpful for developing polypharmacological drugs and
could provide potential candidates for further optimi-
zation. Moreover, the MTLD may shed light on the: side
effects of drugs; multiple functions of small biological
molecules; similarities in binding site of target proteins.
As a crucial expansion of the PDB, increasing numbers of
MTLs will be included in the MTLD, which will become
an efficient platform to obtain useful information on
MTLs.
Availability and requirements
MTLD is freely accessible at http://www.mtdcadd.com.
The data in MTLD is free for search, download, and fur-
ther analysis.
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